Patents by Inventor Rudy Gunawan

Rudy Gunawan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATMENT FOR CYSTIC FIBROSIS
    Publication number: 20220184049
    Abstract: This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof. The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents.
    Type: Application
    Filed: December 9, 2021
    Publication date: June 16, 2022
    Inventors: Bartlomiej Borek, Weichao George Chen, Rudy Gunawan, Eric Haseltine, Nitin Nair, Porntula Panorchan, Patrick Sosnay
  • Conjugated Antisense Compounds for Use in Therapy
    Publication number: 20210169917
    Abstract: Provided herein are methods of administering gapmer oligomeric compounds with GalNAc conjugate groups to a human.
    Type: Application
    Filed: July 28, 2020
    Publication date: June 10, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu, Rudy Gunawan
  • MODULATING APOLIPOPROTEIN (A) EXPRESSION
    Publication number: 20190136233
    Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
    Type: Application
    Filed: November 7, 2016
    Publication date: May 9, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu, Rudy Gunawan
  • CONJUGATED ANTISENSE COMPOUNDS FOR USE IN THERAPY
    Publication number: 20190046555
    Abstract: Provided herein are methods of administering gapmer oligomeric compounds with GalNAc conjugate groups to a human.
    Type: Application
    Filed: November 7, 2016
    Publication date: February 14, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu, Rudy Gunawan